News

Published on 29 Jul 2022 on Benzinga via Yahoo Finance

AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate


Article preview image

AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.The Moderna-partnered candidate is AZD8601, a therapy based on mRNA encoding vascular endothelial growth factor (VEGF-A).In EPICCURE Phase 2a trial, the investigators injected the mRNA directly into the myocardium of patients undergoing elective coronary artery bypass surgery.Related: AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance.Seven patients received AZD8601, and four got the placebo.AstraZeneca touted the results as positive, pointing to trends in the three exploratory endpoints, including left ventricular ejection fraction, an elevated biomarker in heart failure, and functional patient-reported outcomes.However, in its quarterly update, AstraZeneca removed the asset from its phase 2 pipeline. Moderna, the co-developer of AZD8601, still lists the candidate in its pipeline.AstraZeneca also removed Wee1 inhibitor adavosertib from its phase 2 pipeline for r ovarian cancer, solid tumors, and uterine serous cancer.Price Action: MRNA shares are up 2.84% at $162.56, and AZN stock is down 0.63% at $66.30 during the market session on the last check Friday.

See more from Benzinga

NASDAQ.MRNA price evolution
NASDAQ.AZN price evolution
LSE.AZN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Moderna director Noubar Afeyan sells shares worth over $1.5 million By Investing.com

Moderna director Noubar Afeyan sells shares worth over $1.5 million

Investing.com 23 Mar 2024

Cathie Wood's ARK shifts focus, sells COIN and DKNG, buys META and TER By Investing.com

Cathie Wood's ARK shifts focus, sells COIN and DKNG, buys META and TER

Investing.com 22 Mar 2024

Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness

The fact that multiple Moderna, Inc. (NASDAQ:MRNA) insiders offloaded a considerable amount of sh...

Simply Wall St. via Yahoo Finance 22 Mar 2024

Markets News, March 20, 2024: Stocks Climb to Records, Yields Fall as Fed Maintains Rate Cut...

Boeing (BA) shares rose 3.7% as its CFO outlined at a conference in London how the jet maker is...

Investopedia 20 Mar 2024

Why Moderna Shares Are Falling - Moderna (NASDAQ:MRNA)

Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday’s session in possib...

Benzinga 20 Mar 2024

... Of Jack Dorsey-Led Block Yet — Sheds $7.5M Worth of Stock As Bitcoin Price Drops - Block...

On Tuesday, Cathie Wood-led Ark Invest offloaded a significant amount of Block Inc SQ shares amid...

Benzinga 20 Mar 2024

Moderna president Hoge sells $1.55M in company stock By Investing.com

In a recent transaction, Stephen Hoge, the President of Moderna , Inc. (NASDAQ:MRNA), sold shares...

Investing.com 20 Mar 2024

Bluebird secures up to $175M in debt financing deal - Boston Business Journal

Bluebird bio Inc. says it's taken steps to strengthen its balance sheet as the company executes t...

The Business Journals 19 Mar 2024

11 Oversold Biotech Stocks To Buy Right Now

In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip...

Insider Monkey via Yahoo Finance 17 Mar 2024

This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks. Take...

247wallst.com 15 Mar 2024